UY31646A1 - USE OF SUBSTITUTED PHENYLIMIDAZOLIDINS TO PRODUCE MEDICINES FOR THE TREATMENT OF METABOLIC SYNDROME - Google Patents
USE OF SUBSTITUTED PHENYLIMIDAZOLIDINS TO PRODUCE MEDICINES FOR THE TREATMENT OF METABOLIC SYNDROMEInfo
- Publication number
- UY31646A1 UY31646A1 UY031646A UY31646A UY31646A1 UY 31646 A1 UY31646 A1 UY 31646A1 UY 031646 A UY031646 A UY 031646A UY 31646 A UY31646 A UY 31646A UY 31646 A1 UY31646 A1 UY 31646A1
- Authority
- UY
- Uruguay
- Prior art keywords
- treatment
- metabolic syndrome
- substituted
- phenylimidazolidins
- produce
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
El uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico. La invención se refiere al uso de los compuestos de la fórmula I en el que los radicales son cada uno definidos como se especifica para producir un medicamento para el tratamiento del síndrome metabólicoThe use of substituted phenylimidazolidines to produce drugs for the treatment of metabolic syndrome. The invention relates to the use of the compounds of the formula I in which the radicals are each defined as specified to produce a medicament for the treatment of metabolic syndrome.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08290132 | 2008-02-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY31646A1 true UY31646A1 (en) | 2009-08-31 |
Family
ID=39502138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY031646A UY31646A1 (en) | 2008-02-07 | 2009-02-06 | USE OF SUBSTITUTED PHENYLIMIDAZOLIDINS TO PRODUCE MEDICINES FOR THE TREATMENT OF METABOLIC SYNDROME |
Country Status (5)
Country | Link |
---|---|
AR (1) | AR071345A1 (en) |
CL (1) | CL2009000257A1 (en) |
TW (1) | TW200946114A (en) |
UY (1) | UY31646A1 (en) |
WO (1) | WO2009097996A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011140190A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals | Tetrazolones as inhibitors of fatty acid synthase |
AU2016229982B2 (en) | 2015-03-09 | 2020-06-18 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
EP3570841A4 (en) * | 2017-01-18 | 2020-08-19 | Coherus Biosciences, Inc. | PPARy AGONIST FOR THE TREATMENT OF HUNTINGTON'S DISEASE |
EP3606527A1 (en) | 2017-04-03 | 2020-02-12 | Coherus Biosciences, Inc. | Ppar-gamma agonist for treatment of progressive supranuclear palsy |
CN112759550A (en) * | 2019-11-04 | 2021-05-07 | 上海科技大学 | Smooth receptor antagonist |
CN113024513A (en) * | 2021-03-22 | 2021-06-25 | 中国药科大学 | Novel androgen receptor degradation agent, preparation method and medical application |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2693461B1 (en) * | 1992-07-08 | 1994-09-02 | Roussel Uclaf | New substituted phenylimidazolidines, process for their preparation, their use as medicaments and the pharmaceutical compositions containing them. |
-
2009
- 2009-01-30 WO PCT/EP2009/000589 patent/WO2009097996A1/en active Application Filing
- 2009-02-05 CL CL2009000257A patent/CL2009000257A1/en unknown
- 2009-02-05 TW TW098103592A patent/TW200946114A/en unknown
- 2009-02-05 AR ARP090100397A patent/AR071345A1/en unknown
- 2009-02-06 UY UY031646A patent/UY31646A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR071345A1 (en) | 2010-06-16 |
WO2009097996A1 (en) | 2009-08-13 |
TW200946114A (en) | 2009-11-16 |
CL2009000257A1 (en) | 2009-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201500077A (en) | NOVELTY BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | |
CU20140048A7 (en) | NEW PURINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | |
CO6781507A2 (en) | Novel heterocyclic derivatives | |
UY32094A (en) | HETEROCYCLIC DERIVATIVES, PROCESSES FOR THEIR PREPARATION, DRUGS THAT INCLUDE SUCH COMPOUNDS AND THEIR USE. | |
CR20140161A (en) | BENZILINDAZOLS REPLACED FOR USE AS INHIBITORS OF QUINASA BUB1 IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | |
CR20150326A (en) | AUTOTAXIN INHIBITORS | |
CU20130036A7 (en) | TRIAZINA-OXIDAZOLES | |
CU20120099A7 (en) | DERIVATIVES OF PIRAZINA AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | |
DOP2014000115A (en) | USE OF SUBSTITUTED 4-PHENYL-PYRIDINS FOR THE MANUFACTURE OF USEFUL MEDICINES IN THE TREATMENT OF DISEASES RELATED TO THE NK1 RECEIVER | |
CO6771417A2 (en) | Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis | |
CR20140525A (en) | N-alkyltriazole compounds as LPAR antagonists | |
CO6751268A2 (en) | Novel cyclic azabenzimidazole derivatives useful as antidiabetic agents | |
UY33458A (en) | HETEROCYCLICALLY SUBSTITUTED METOXYPHENYL DERIVATIVES WITH AN OXO GROUP, PROCEDURES FOR THE PREPARATION AND USE OF THE SAME AS MEDICATIONS | |
UY31053A1 (en) | HETEROCICLICAL DERIVATIVES, PROCESSES FOR THEIR PRODUCTION, DRUGS THAT UNDERSTAND THESE COMPOUNDS AND THEIR USE | |
UY31645A1 (en) | NEW PHENYL-SUBSTITUTED IMIDAZOLIDINS, PROCEDURE FOR PREPARATION, MEDICATIONS THAT INCLUDE SUCH COMPOUNDS AND THEIR USE. | |
NI201500050A (en) | BENZAMIDES | |
ECSP14013215A (en) | NEW COMPOUNDS | |
UY33817A (en) | ? NEW BENCYLIC OXINDOLPIRIMIDINES ?. | |
CR20130569A (en) | EPOXIEICOSATRIENOIC ACID ANALOGS AND METHODS OF TAKING AND USING THE SAME | |
ECSP14002542A (en) | NOVEL 2HINDAZOLES AS EP2 RECEPTOR ANTAGONISTS | |
CO7350640A2 (en) | Dimeric compounds | |
UY35906A (en) | NEWS DERIVED FROM BENCIMIDAZOL AS LIGANDOS OF EP4 | |
CO6341625A2 (en) | DERIVATIVES OF INDOL AS ANTI-CANCER AGENTS | |
UY31646A1 (en) | USE OF SUBSTITUTED PHENYLIMIDAZOLIDINS TO PRODUCE MEDICINES FOR THE TREATMENT OF METABOLIC SYNDROME | |
CR20150148A (en) | AZAINDOLINS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20130513 |